NEW YORK, May 30, 2017 -- Drone USA, Inc. (OTC Markets:DRUS) (“Drone USA” or the “Company”), a developer and manufacturer of low altitude Unmanned Aerial Vehicles (“UAVs”) and related technologies, today announced that it received a purchase order for a Shadow Police Drone from a Connecticut Police Department.
Michael Bannon, Drone USA’s Chief Executive Officer, commented: “We are excited about aggressively entering into the U.S. police drone market. Our goal is to start in New England and then move south and west into New York, New Jersey and Pennsylvania. Our shadow drones can be used for search and rescue, surveillance, crowd control, crime and traffic scene analysis, active shooter and bomb inspection. In late June we intend to demonstrate our fixed-wing Cyclops to several Connecticut Police Departments on a public beach in Connecticut. We want to demonstrate Cyclops’ value as an inexpensive water search and rescue tool.; it can locate boaters in distress or swimmers who ventured too far from shore. We also intend to offer Cyclops to Cape Cod and mainland Massachusetts coastline Police Departments as an inexpensive way to monitor great white shark activity.”
About Drone USA, Inc.
Headquartered at One World Trade Center in New York, NY, Drone USA is a primary developer and manufacturer of low altitude unmanned aerial vehicles (UAV) and related technologies. Target markets include select defense segments (military), public safety (police, fire, emergency response), and high growth commercial applications such as agriculture, photogrammetry, mining, utilities, and entertainment. The Company seeks to strengthen its systems portfolio by acquiring UAV firms with superior technologies that are proven in high-growth markets, as well as complementary technologies such as sensors and software.
For additional information about Drone USA, please visit www.droneusainc.com.
Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of growth; and assumptions relating to the foregoing. Such forward-looking statements are generally qualified by terms such as: “plans, “anticipates,” “expects,” “believes” or similar words of like kind. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. These factors are discussed in greater detail in the company’s business plan and filings with the OTC Markets Group.
CONTACT: Michael Bannon Chief Executive Officer [email protected]


Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 



